Illumina, Inc.: These Are The 3 Biggest Challenges In Its Path! 

Illumina experienced a mixed third-quarter performance for 2024, illustrating both advancements and challenges in its operational landscape. The company reported quarterly revenue of $1.1 billion, matching its expectations but reflecting a 2% decrease year-over-year. This decline was linked to reduced instrument sales due to the launch-year comparisons of the NovaSeq X series and effects of capital constraints globally. However, Illumina saw a 7% rise in sequencing consumables, driven by the anticipated uptake of the NovaSeq X platform.